Latest News for: kinase inhibitor

Edit

Cyclin-Dependent Kinase Inhibitor Pipeline Appears Robust With 45+ Key Pharma Companies Actively Working in the ...

GetNews 16 Jul 2025
Inactive Products Cyclin-Dependent Kinase Inhibitor Key Companies Cyclin-Dependent Kinase Inhibitor Key Products Cyclin-Dependent Kinase Inhibitor- Unmet Needs Cyclin-Dependent Kinase Inhibitor- ...
Edit

Emerging viral threats combated by a potent new dual lipid kinase inhibitor

Phys Dot Org 14 Jul 2025
Kinases have been successfully utilized as drug targets for the past 30 years, with nearly 90 kinase inhibitors approved by the FDA mostly for the treatment of cancers and inflammatory diseases.
Edit

Kinase Inhibitors in Autoimmune Diseases Market Research 2025-2035, Featuring Pfizer, Eli Lilly and Co, Reistone ...

The Galveston Daily News 27 Jun 2025
DUBLIN--(BUSINESS WIRE)--Jun 27, 2025-- ....
Edit

Kinase Inhibitors in Autoimmune Diseases Research Report 2025-2035 | Market Accelerates Amid Rising Disease Prevalence, ...

Nasdaq Globe Newswire 24 Jun 2025
The global kinase inhibitors in autoimmune diseases market is experiencing significant growth, driven by rising autoimmune disease prevalence and advancements in biotechnology, specifically in targeted therapies like JAK inhibitors.
Edit

IMpactMF, Randomized, Open-Label, Phase 3 Trial of Imetelstat Versus Best Available Therapy In Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitors (Geron Corporation)

Public Technologies 13 Jun 2025
IMPACTMF, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED OR REFRACTORY TO JANUS KINASE INHIBITORS.
  • 1

Article Search

tools
×
×
×
×